Verapamil antagonizes forearm vasoconstriction mediated by selective alpha 1- and alpha 2-agonists in hypertensive patients. 1986

R Pedrinelli, and S Taddei, and L Graziadei, and G Panarace, and A Salvetti

Calcium channel blocking agents preferentially antagonize alpha 2-mediated pressor responses in various animal species. Whether the same happens in man is not clear. For this reason we studied the interference exerted by verapamil, a calcium entry blocker, on forearm vasoconstriction mediated by selective alpha 1- (methoxamine) and alpha 2- (B-HT 933) adrenergic agonists in untreated mild-to-moderately hypertensive patients (n = 22). Each patient underwent a single study. Forearm blood flow was recorded by strain gauge venous plethysmography; all drugs were infused into the brachial artery at systemically ineffective rates. Cumulative dose-response curves to intra-arterial methoxamine or B-HT 933 were obtained during saline or two different rates of verapamil infusion (0.9 and 3.1 micrograms/100 ml forearm tissue per min) which increased forearm blood flow dose-dependently without changing systemic blood pressure or heart rate. Either methoxamine or B-HT 933 decreased forearm blood flow during saline infusion, but their effect was blunted in a dose-dependent manner during verapamil. No evidence of preferential alpha 2-antagonism was present. At variance with animal data, calcium entry blockade by verapamil antagonizes either alpha 1- or alpha 2-mediated vasoconstriction in human forearm vessels.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008729 Methoxamine An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION. Methoxamedrin,Methoxamine Hydrochloride,Metoxamine Wellcome,Vasoxin,Vasoxine,Vasoxyl,Vasylox,Hydrochloride, Methoxamine,Wellcome, Metoxamine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005542 Forearm Part of the upper extremity in humans and primates extending from the ELBOW to the WRIST. Antebrachium,Antebrachiums,Forearms
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000316 Adrenergic alpha-Agonists Drugs that selectively bind to and activate alpha adrenergic receptors. Adrenergic alpha-Receptor Agonists,alpha-Adrenergic Receptor Agonists,Adrenergic alpha-Agonist,Adrenergic alpha-Receptor Agonist,Receptor Agonists, Adrenergic alpha,Receptor Agonists, alpha-Adrenergic,alpha-Adrenergic Agonist,alpha-Adrenergic Agonists,alpha-Adrenergic Receptor Agonist,Adrenergic alpha Agonist,Adrenergic alpha Agonists,Adrenergic alpha Receptor Agonist,Adrenergic alpha Receptor Agonists,Agonist, Adrenergic alpha-Receptor,Agonist, alpha-Adrenergic,Agonist, alpha-Adrenergic Receptor,Agonists, Adrenergic alpha-Receptor,Agonists, alpha-Adrenergic,Agonists, alpha-Adrenergic Receptor,Receptor Agonist, alpha-Adrenergic,Receptor Agonists, alpha Adrenergic,alpha Adrenergic Agonist,alpha Adrenergic Agonists,alpha Adrenergic Receptor Agonist,alpha Adrenergic Receptor Agonists,alpha-Agonist, Adrenergic,alpha-Agonists, Adrenergic,alpha-Receptor Agonist, Adrenergic,alpha-Receptor Agonists, Adrenergic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001381 Azepines Seven membered heterocyclic rings containing a NITROGEN atom. Hexamethyleneimines

Related Publications

R Pedrinelli, and S Taddei, and L Graziadei, and G Panarace, and A Salvetti
January 1986, Journal of cardiovascular pharmacology,
R Pedrinelli, and S Taddei, and L Graziadei, and G Panarace, and A Salvetti
December 1985, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
R Pedrinelli, and S Taddei, and L Graziadei, and G Panarace, and A Salvetti
January 1987, European journal of clinical pharmacology,
R Pedrinelli, and S Taddei, and L Graziadei, and G Panarace, and A Salvetti
June 1990, Clinical pharmacology and therapeutics,
R Pedrinelli, and S Taddei, and L Graziadei, and G Panarace, and A Salvetti
January 1985, Journal of cardiovascular pharmacology,
R Pedrinelli, and S Taddei, and L Graziadei, and G Panarace, and A Salvetti
August 1987, The American journal of physiology,
R Pedrinelli, and S Taddei, and L Graziadei, and G Panarace, and A Salvetti
December 1984, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
R Pedrinelli, and S Taddei, and L Graziadei, and G Panarace, and A Salvetti
July 1987, International journal of clinical pharmacology, therapy, and toxicology,
R Pedrinelli, and S Taddei, and L Graziadei, and G Panarace, and A Salvetti
November 1985, Archives internationales de pharmacodynamie et de therapie,
R Pedrinelli, and S Taddei, and L Graziadei, and G Panarace, and A Salvetti
January 1993, European journal of pharmacology,
Copied contents to your clipboard!